

## HanaVax Inc. and YISHENG BIOPHARMA CO., LTD. developing novel pneumococcal vaccine for China

HanaVax Inc. (Headquarter: Tokyo, Japan, President & CEO Pohsing Ng); a nasal vaccine developing biotech company and YISHENG BIOPHARMA CO., LTD. (Headquarter: Beijing, China, President CEO David Shao); a global biopharma company based in China have mutually agreed to co-development and co-commercialization of pneumococcal vaccine for Chinese market. Both parties will negotiate in good faith to determine the responsibility and commercial terms for the announced project by end of year 2019.

### About YISHENG BIOPHARMA CO., LTD.

---

Founded in 2002, YISHENG BIOPHARMA CO., LTD. is a global, fully integrated biopharmaceutical company engaged in discovering, developing and commercializing innovative biotherapeutics for cancer and infectious disease using its novel PIKA<sup>®</sup> immunomodulating technology. The Company has two marketed products in China and South East Asia market. Yisheng Biopharma is headquartered in Beijing with approximately 640 employees in China, Singapore, Cambodia and the U.S.

[www.yishengbio.com](http://www.yishengbio.com)

HanaVax Inc.

Founded : Dec 2016

CEO & President : Ng Pohsing

HQ : Tokyo, Japan

Business : Developing nasal vaccine for infectious diseases

[www.hanavax.co.jp](http://www.hanavax.co.jp)

Learn more

